Article
The first in-human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT-678 in acute coronary syndrome patients and healthy volunteers.
British journal of pharmacology - 1 Jan 2025
Liu Zhihao, Liu Shengcong, Gong Yanjun, Chi Xiying, Wang Ting, Fan Fangfang, Qu Chenxue, Lou Yaxin, Zhang Long, Zhang Bin, Yang Fan, Mohetaboer Momin, Wang Jie, Qiu Lin, Miao Linzi, Lu Yao, You Ran, He Pengkang, Li Yuxi, Yi Tieci, Weng Haoyu, Xia Yulong, Wang Chunyan, Shi Qiuping, Wang Zhi, Jiang Yimeng, Li Yinjuan, Han Chunyu, Wang Yu, Wang Xinghe, Yang Caixia, Chen Y Eugene, Eitzman Daniel T, Zhang Haoming, Li Jianping
Abstract excerpt
BACKGROUND AND PURPOSE: DT-678 is a novel antiplatelet prodrug, capable of releasing the antiplatelet active metabolite of clopidogrel (AM) upon exposure to glutathione. In this study, we investigated factors responsible for clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients and evaluated the capacity of DT-678 to overcome HTPR. EXPERIMENTAL APPROACH: A total of 300...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.